sur Kexing Biopharm
Kexing Biopharm Wraps Up Successful CPHI & PMEC China 2026 Participation
Kexing Biopharm successfully concluded its participation in the CPHI & PMEC China 2026, held from June 16 to 18 at the Shanghai New International Expo Center. The company showcased its innovative drug pipelines and over 30 products aimed at international markets. During the event, Kexing Biopharm received the R&D Innovation Award, acknowledging its advancements in technology platforms and breakthroughs in R&D innovation.
The company presented products across oncology, autoimmunity, and metabolic diseases. Notably, drugs like albumin-bound paclitaxel and bevacizumab attracted significant interest. Additionally, Kexing Biopharm emphasized key R&D projects with global potential, such as GB18 for cancer cachexia and GB19/GB26 for systemic lupus erythematosus.
Engagement in forums addressing international biopharmaceutical commercialization further supported Kexing Biopharm's global expansion strategy, offering significant insights into optimizing international pathways.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Kexing Biopharm